Summit Therapeutics Appoints New CMO and CSO, Adds to Board
Ticker: SMMT · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $100,000, $430,000, $5,000,000, $1.68 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-of-directors, personnel-change
TL;DR
Summit Therapeutics beefs up leadership with new CMO/CSO and board members.
AI Summary
Summit Therapeutics Inc. announced on April 2, 2024, the appointment of Dr. Jonathan Edward as Chief Medical Officer and Dr. Kevin J. Lee as Chief Scientific Officer. The company also reported the election of Dr. Edward and Dr. Lee to its Board of Directors. These appointments are effective immediately.
Why It Matters
The appointment of key scientific and medical leadership positions is crucial for advancing Summit Therapeutics' drug development pipeline and strategic direction.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate strategic shifts or challenges within a company, requiring careful monitoring.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- Dr. Jonathan Edward (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Dr. Kevin J. Lee (person) — Appointed Chief Scientific Officer and elected to Board of Directors
- April 2, 2024 (date) — Effective date of appointments
FAQ
What are the specific responsibilities of the new Chief Medical Officer and Chief Scientific Officer?
The filing states their appointments but does not detail specific responsibilities beyond their titles.
Are there any immediate strategic changes expected due to these appointments?
The filing does not explicitly mention any immediate strategic changes, but the appointments are effective immediately.
What is the prior experience of Dr. Jonathan Edward and Dr. Kevin J. Lee?
The filing does not provide details on the prior experience of the newly appointed officers.
Were there any departures of directors or officers that preceded these appointments?
The filing lists 'Departure of Directors or Certain Officers' as an item information, but does not specify if any departures occurred immediately prior to these appointments.
What is the expected impact of these appointments on Summit Therapeutics' current drug development programs?
The filing does not specify the expected impact on current drug development programs.
Filing Stats: 1,059 words · 4 min read · ~4 pages · Grade level 11.3 · Accepted 2024-04-03 16:42:10
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
- $100,000 — a one-time cash bonus in the amount of $100,000 and 1,100,000 options to purchase share
- $430,000 — comprised of (i) annual base salary of $430,000, (ii) a bonus opportunity of up to 40%
- $5,000,000 — On October 13, 2023, Mr. Soni invested $5,000,000 in the Company in a private placement i
- $1.68 — of Common Stock at a purchase price of $1.68 per share. Except as described herein,
- $7.5 billion — es and assisted with the execution of a $7.5 billion merger transaction with Biogen while at
Filing Documents
- smmt-20240402.htm (8-K) — 33KB
- 0001599298-24-000051.txt ( ) — 184KB
- smmt-20240402.xsd (EX-101.SCH) — 2KB
- smmt-20240402_def.xml (EX-101.DEF) — 14KB
- smmt-20240402_lab.xml (EX-101.LAB) — 25KB
- smmt-20240402_pre.xml (EX-101.PRE) — 15KB
- smmt-20240402_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: April 3, 2024 By: /s/ Robert W. Duggan Chief Executive Officer (Principal Executive Officer)